Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results

Prof Stefano Luminari - University of Modena and Reggio Emilia, Modena, Italy
Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results ( Prof Stefano Luminari - University of Modena and Reggio Emilia, Modena, Italy )
9 Jul 2025

Managing cardiotoxicities for RCC treatment – Cardiologist’s perspective

Dr Ricky Frazer and Dr Rebecca Dobson
Managing cardiotoxicities for RCC treatment – Cardiologist’s perspective ( Dr Ricky Frazer and Dr Rebecca Dobson )
7 Jul 2025

Bexmarilimab plus azacitidine shows promising response in relapsed/refractory myelodysplasia

Dr Anthony Stein - City of Hope, Duarte, USA
Bexmarilimab plus azacitidine shows promising response in relapsed/refractory myelodysplasia ( Dr Anthony Stein - City of Hope, Duarte, USA )
27 Jun 2025

Subcutaneous isatuximab via on-body delivery system matches IV efficacy with better experience in RRMM

Prof Xavier Leleu - Poitiers University Hospital, Poitiers, France
Subcutaneous isatuximab via on-body delivery system matches IV efficacy with better experience in RRMM ( Prof Xavier Leleu - Poitiers University Hospital, Poitiers, France )
27 Jun 2025

Triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibodies

Dr Moritz Fürstenau - University of Cologne, Cologne, Germany
Triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibodies ( Dr Moritz Fürstenau - University of Cologne, Cologne, Germany )
27 Jun 2025

The combination of acimtamig and AlloNK therapy demonstrates promising efficacy in R/R cHL

Dr Amitkumar Mehta - University of Alabama at Birmingham, Birmingham, USA
The combination of acimtamig and AlloNK therapy demonstrates promising efficacy in R/R cHL ( Dr Amitkumar Mehta - University of Alabama at Birmingham, Birmingham, USA )
27 Jun 2025

Key insights from lung cancer research at ASCO 2025

Dr Luis Raez - Memorial Cancer Institute, Miami, USA
Key insights from lung cancer research at ASCO 2025 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )
27 Jun 2025

POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse large B-cell lymphoma

Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA
POLA-R-GEMOX  regimen is a promising option for relapsed/refractory diffuse large B-cell lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )
27 Jun 2025

ASCO 2025: Importance of early testing in metastatic prostate cancer

Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida Maiorano
ASCO 2025: Importance of early testing in metastatic prostate cancer ( Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida Maiorano )
3 Jun 2025

Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial bladder cancer

Dr Brigida Maiorano - IRCCS San Raffaele Hospital, Milan, Italy
Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial bladder cancer ( Dr Brigida Maiorano - IRCCS San Raffaele Hospital, Milan, Italy )
3 Jun 2025

ctDNA-guided chemo escalation does not improve recurrence-free survival in stage III colon cancer

Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia
ctDNA-guided chemo escalation does not improve recurrence-free survival in stage III colon cancer ( Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia )
2 Jun 2025

Disparities in mammogram screening amongst LGBTQ+ populations

Dr Manas Pustake - Texas Tech University Health Science Center, El Paso, USA
Disparities in mammogram screening amongst LGBTQ+ populations ( Dr Manas Pustake - Texas Tech University Health Science Center, El Paso, USA )
2 Jun 2025